- Home
- SRBK vs BOLD Comparison
SRBK vs BOLD Comparison
Compare SRBK & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRBK
- BOLD
- Stock Information
- Founded
- SRBK 1887
- BOLD 2018
- Country
- SRBK United States
- BOLD United States
- Employees
- SRBK N/A
- BOLD N/A
- Industry
- SRBK
- BOLD
- Sector
- SRBK
- BOLD
- Exchange
- SRBK Nasdaq
- BOLD Nasdaq
- Market Cap
- SRBK 96.1M
- BOLD 81.0M
- IPO Year
- SRBK N/A
- BOLD 2024
- Fundamental
- Price
- SRBK $10.67
- BOLD $2.95
- Analyst Decision
- SRBK
- BOLD Strong Buy
- Analyst Count
- SRBK 0
- BOLD 3
- Target Price
- SRBK N/A
- BOLD $23.00
- AVG Volume (30 Days)
- SRBK 20.6K
- BOLD 57.8K
- Earning Date
- SRBK 01-01-0001
- BOLD 11-11-2024
- Dividend Yield
- SRBK N/A
- BOLD N/A
- EPS Growth
- SRBK N/A
- BOLD N/A
- EPS
- SRBK N/A
- BOLD N/A
- Revenue
- SRBK $22,814,000.00
- BOLD N/A
- Revenue This Year
- SRBK N/A
- BOLD N/A
- Revenue Next Year
- SRBK N/A
- BOLD N/A
- P/E Ratio
- SRBK N/A
- BOLD N/A
- Revenue Growth
- SRBK 52.54
- BOLD N/A
- 52 Week Low
- SRBK $8.01
- BOLD $2.82
- 52 Week High
- SRBK $11.24
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- SRBK 51.76
- BOLD N/A
- Support Level
- SRBK $10.97
- BOLD N/A
- Resistance Level
- SRBK $11.09
- BOLD N/A
- Average True Range (ATR)
- SRBK 0.06
- BOLD 0.00
- MACD
- SRBK -0.05
- BOLD 0.00
- Stochastic Oscillator
- SRBK 5.50
- BOLD 0.00
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.